Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.

Paunovic I, Isic T, Havelka M, Tatic S, Cvejic D, Savin S.

APMIS. 2012 May;120(5):368-79. doi: 10.1111/j.1600-0463.2011.02842.x. Epub 2011 Nov 19.

PMID:
22515291
2.

Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential.

Papotti M, Rodriguez J, De Pompa R, Bartolazzi A, Rosai J.

Mod Pathol. 2005 Apr;18(4):541-6.

PMID:
15529186
3.

Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.

Mataraci EA, Ozgüven BY, Kabukçuoglu F.

Pol J Pathol. 2012 Mar;63(1):58-64.

PMID:
22535608
4.

Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.

Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park DJ, Jang HC, Park SH, Cho BY, Park SY.

J Korean Med Sci. 2007 Aug;22(4):621-8.

PMID:
17728499
5.

Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.

Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X, Zhu X.

J Clin Pathol. 2010 Sep;63(9):786-9. doi: 10.1136/jcp.2010.076901. Epub 2010 Jul 19.

PMID:
20644217
7.

Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.

Abd-El Raouf SM, Ibrahim TR.

Pathol Res Pract. 2014 Dec;210(12):971-8. doi: 10.1016/j.prp.2014.06.010. Epub 2014 Jun 27.

PMID:
25041837
8.

Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.

Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, Rumilla K, Lloyd RV.

Endocr Pathol. 2006 Fall;17(3):213-23.

PMID:
17308358
9.

[Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1].

Tang QS, Teng XD, Ding W, Zhou J, Yao HT, Ying LX, Xu LM.

Zhonghua Bing Li Xue Za Zhi. 2011 Nov;40(11):745-8. Chinese.

PMID:
22336157
10.

Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19.

Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO.

Endocr Pathol. 2010 Jun;21(2):80-9. doi: 10.1007/s12022-010-9114-y.

PMID:
20198455
11.

Immunohistochemical diagnosis of papillary thyroid carcinoma.

Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL.

Mod Pathol. 2001 Apr;14(4):338-42.

PMID:
11301350
12.

The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer.

Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR.

Am J Clin Pathol. 2004 Oct;122(4):524-31.

PMID:
15487449
13.

Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.

Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos AP, Orlandi F, Papotti M.

Endocr Relat Cancer. 2005 Jun;12(2):305-17.

PMID:
15947105
14.

The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma.

Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M.

Exp Oncol. 2006 Mar;28(1):70-4.

PMID:
16614712
15.

Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.

Saleh HA, Jin B, Barnwell J, Alzohaili O.

Diagn Pathol. 2010 Jan 26;5:9. doi: 10.1186/1746-1596-5-9.

PMID:
20181018
16.

[Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms].

Bogdańska M, Górnicka B, Ziarkiewicz-Wróblewska B, Koperski L, Morton M, Wasiutyński A.

Endokrynol Pol. 2006 Jul-Aug;57(4):314-9. Polish.

PMID:
17006830
17.

Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions.

Oestreicher-Kedem Y, Halpern M, Roizman P, Hardy B, Sulkes J, Feinmesser R, Stern Y.

Head Neck. 2004 Nov;26(11):960-6.

PMID:
15386597
18.

Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.

Rossi ED, Raffaelli M, Mule' A, Miraglia A, Lombardi CP, Vecchio FM, Fadda G.

Histopathology. 2006 Jun;48(7):795-800.

PMID:
16722927
19.

[Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases].

Yang QX, Shao CK, Feng ZY, Huang BQ, Han AJ, Xiong M, Zhao WL, Wu TT.

Di Yi Jun Yi Da Xue Xue Bao. 2005 Jun;25(6):678-81. Chinese.

PMID:
15958307
20.

Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.

Dunđerović D, Lipkovski JM, Boričic I, Soldatović I, Božic V, Cvejić D, Tatić S.

Diagn Pathol. 2015 Oct 26;10:196. doi: 10.1186/s13000-015-0428-4.

PMID:
26503236
Items per page

Supplemental Content

Write to the Help Desk